INTERSOLAR-EUROPE
22.4.2022 09:41:05 CEST | Business Wire | Press release
At the Intersolar Europe exhibition, established and new players in the energy sector exchange information about new developments and trends, experience innovations and exploit business potential. The focus of the world’s leading exhibition for the solar industry is, among other things, the dual use of areas in agriculture, on bodies of water and in buildings. Intersolar Europe will be held at Messe München from May 11 to 13.
Photovoltaic (PV) production is booming in Germany and throughout Europe: almost 26 gigawatts (GW) of PV installations were connected to the grid in the EU in 2021 – a record growth of 34%. As in the previous year, Germany was the largest PV market in the EU with an addition of 5.3 GW. The European inter-trade organization, SolarPower Europe, expects installed solar power capacity to double to more than 326 GW by 2025.
At Intersolar Europe 2022, companies will present innovations and products developed for the world of new energies. Some examples include Agri-photovoltaics and Floating PV. The efficient dual use of areas for agriculture and solar power generation is developing dynamically: in 2020, plants for the generation of more than 14 GW had already been installed worldwide, according to the Fraunhofer Institute for Solar Energy Systems (ISE). Floating PV is now considered the third pillar of the global solar market. An estimated 400 plants with a total capacity of more than 3 GW are already in operation in over 40 countries. At Intersolar Europe 2022, these rapid developments will be prominent, with a large number of exhibitors presenting innovative products and solutions from the Agri-PV and Floating PV sectors.
Building-integrated PV (BIPV) is another key topic at Intersolar Europe 2022. With a view to the German market, this is where the greatest potential can be found for reducing the CO2 footprint of buildings, using space efficiently and strengthening sustainable development.
Intersolar Europe forms part of The smarter E Europe. From May 11 to 13, 2022, it will present cross-industry and cross-sector solutions for the energy transition and security of supply in Europe at Messe München. 1,450 exhibitors will showcase products, solutions and business models across 132,000 square meters in twelve exhibition halls.
Topics such as Agri-PV, Floating PV and BIPV will also be addressed at the Intersolar Europe Conference on May 10 and 11, 2022 at the International Congress Center Munich (ICM). Participants will learn all about the markets, technologies and financing of PV projects. One area under the spotlight will be large-scale PV power plants and systems, especially with regard to Agri-PV and floating PV. On May 10 at 6 p.m., innovators and experts will be honored with the Intersolar AWARD at the ICM (Hall 1).
https://www.intersolar.de/home?lang=en
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220421005509/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bial Announces Completion of Phase 2b ACTIVATE Study with BIA 28-6156 in GBA1-Associated Parkinson’s26.5.2026 08:00:00 CEST | Press release
Study Topline results will be released around the end of Q2 2026 BIA 28-6156 is being developed as a potential first-in-class disease-modifying therapy in GBA-PD Bial was present at the GBA1 conference and is currently attending the World Parkinson Congress Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced the completion of the treatment period in its Phase 2b ACTIVATE study of BIA 28-6156 (pariceract) in patients with Parkinson’s disease (PD) who have a pathogenic mutation in the glucocerebrosidase 1 (GBA1) gene (GBA-PD). Upon completion of the 78-week double-blind treatment period and all scheduled safety follow-ups, data cleaning and analysis are currently ongoing. Topline results will be released around the end of Q2. A status report on the ACTIVATE study was presented in an oral presentation at the 3rd International GBA1 Meeting 2026. The team is currently attending the 7th World Parkinson Congress, taking place in Pho
Oticon Medical Introduces Ponto™ Instant, Expanding Non-Surgical Choice with Instant HearBand and Instant SoundConnector26.5.2026 07:00:00 CEST | Press release
Oticon Medical today announces its new non-surgical portfolio, Ponto Instant, designed to broaden access to bone conduction hearing and offer more choice for users and hearing care professionals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525771593/en/ Left: Instant HearBand, a discreet behind-the-head wearable solution that offers an alternative to Softband 5. Right: Instant SoundConnector, a small accessory fitted to a cap or other headwear, providing another non-surgical way to wear a Ponto sound processor. The Ponto Instant portfolio includes Softband 5, Oticon Medical’s established and trusted non-surgical solution, and now expands with the launch of Instant HearBand and Instant SoundConnector, further strengthening its wearable offering for children and adults who prefer a non-surgical solution. Instant HearBand: a discreet new wearable alternative As part of the new portfolio, Instant HearBand is introduced as
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom